Asian Spectator

Times Advertising

Clarity receives US FDA Fast Track Designation for the treatment of metastatic castration-resistant prostate cancer patients with Cu-67 SAR-bisPSMA

  • Written by PR Newswire Asia - Asian Spectator
Clarity receives US FDA Fast Track Designation for the treatment of metastatic castration-resistant prostate cancer patients with Cu-67 SAR-bisPSMA

SYDNEY, Feb. 19, 2025 /PRNewswire/ -- Clarity Pharmaceuticals (ASX: CU6) ("Clarity" or "Company"), a clinical-stage radiopharmaceutical company with a mission to develop next-generation products that improve treatment outcomes for children and adults with cancer, is pleased to announce that the United States (US) Food and Drug Administration (FDA)...

Magazine

Legal Risks Every Business Owner Should Know

Running a business in Australia comes with a degree of legal exposure that many owners underestimate until a problem is already at their door. From contractual disputes to employment matters, the le...

Jerat algoritma: AI perburuk beban ganda ojol dan kurir perempuan di Indonesia

● Sistem AI mengeksploitasi tenaga kerja informal melalui ekstraksi data dan pengalihan risiko kepada mereka.● Algoritma merugikan perempuan karena mengabaikan realitas beban domestik, isu...

Narasi “kebangkitan batu bara” bermunculan efek perang Iran, tapi data menunjukkan fakta sebaliknya

● Di tengah krisis energi global, data menunjukkan penggunaan batu bara dan gas justru turun, sementara energi terbarukan meningkat.● Tren penurunan ekspor baru bara di Indonesia sudah ter...